Print this page    •   Back to Web version of article

TMC278 (Rilpivirine) Stands Up to Efavirenz in Battle of First-Line NNRTIs; FDA Approval May Be Drawing Near

By Myles Helfand

July 28, 2010

Myles is the editorial director of TheBody.com and TheBodyPRO.com.

The NNRTI efavirenz (EFV, Sustiva, Stocrin) is one of the most popular first-line HIV medications, but its risk of associated neurological side effects sometimes leaves people seeking other options. An NNRTI in late-stage development, TMC278 (rilpivirine), appears firmly set on offering treatment-naive people a viable alternative.

It's too soon to predict whether TMC278 will succeed in that goal. But research presented at AIDS 2010 appears to support this young upstart's progress toward U.S. Food and Drug Administration (FDA) approval, perhaps within the next several months.

The Gist

For a more detailed breakdown of the ECHO and THRIVE 48-week results, take a look at the abstract of the AIDS 2010 presentation by Cal Cohen, M.D., or read Mark Mascolini's lovely recap of the study details at NATAP.org. We also hope to add the slides from Cohen's presentation to this page soon.

Read more of The Viral Truth, a TheBody.com blog.

Get e-mail notifications every time The Viral Truth is updated.


Copyright © 2010 Body Health Resources Corporation. All rights reserved.




This article was provided by TheBodyPRO.com. It is a part of the publication The XVIII International AIDS Conference. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art57874.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.